U.S.-listed shares of Midatech Pharma PLC ADR soared 35.7% in premarket trading on Wednesday after the company said the Food and Drug Administration granted Fast Track status to the treatment it’s developing for recurrent glioblastoma, a fast-growing brain tumor. Midatech’s stock is down 40.3% this year, while the S&P 500 has declined 13.3%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
